» Articles » PMID: 16804192

OxLDL Immune Complexes Activate Complement and Induce Cytokine Production by MonoMac 6 Cells and Human Macrophages

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2006 Jun 29
PMID 16804192
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidized low density lipoprotein (OxLDL) is immunogenic and induces autoimmune responses in humans. OxLDL antibodies are predominantly of the proinflammatory IgG1 and IgG3 isotypes. We tested the capacity of immune complexes prepared with copper-oxidized human LDL and affinity chromatography-purified human OxLDL antibodies [OxLDL-immune complexes (ICs)] to activate complement and to induce cytokine release by MonoMac 6 (MM6) cells and by primary human macrophages. The levels of C4d and C3a were significantly higher in human serum incubated with OxLDL-ICs than after incubation with OxLDL or OxLDL antibody, indicating complement activation by the classical pathway. MM6 cells and primary human macrophages were incubated with OxLDL-ICs, with or without prior conditioning with interferon-gamma. After 18 h of incubation, both MM6 cells and primary human macrophages released significantly higher levels of proinflammatory cytokines after incubation with OxLDL-ICs than after incubation with OxLDL or with OxLDL antibody, both in primed and unprimed cells. OxLDL-ICs were more potent activators of MM6 cells than keyhole limpet hemocyanin-ICs. Blocking Fc gamma receptor I (FcgammaRI) with monomeric IgG1 significantly depressed the response of MM6 cells to OxLDL-ICs. In conclusion, human OxLDL-ICs have proinflammatory properties, as reflected by their capacity to activate the classical pathway of complement and to induce proinflammatory cytokine release from MM6 cells and primary human macrophages.

Citing Articles

Redox regulation of the immune response.

Morris G, Gevezova M, Sarafian V, Maes M Cell Mol Immunol. 2022; 19(10):1079-1101.

PMID: 36056148 PMC: 9508259. DOI: 10.1038/s41423-022-00902-0.


Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect.

Hong D, Lee D, Lee J, Lee E, Park S, Lee M Int J Mol Sci. 2022; 23(15).

PMID: 35955522 PMC: 9369234. DOI: 10.3390/ijms23158384.


Physicochemical Characterization of LDL Glycation and Its Inhibition by Ellagic Acid (EA): An Approach to Inhibit Diabetes in Experimental Animals.

Ahmad S, Alouffi S, Khan S, Khan M, Akasha R, Ashraf J Biomed Res Int. 2022; 2022:5583298.

PMID: 35097119 PMC: 8791751. DOI: 10.1155/2022/5583298.


Involvement of enhanced expression of classical complement C1q in atherosclerosis progression and plaque instability: C1q as an indicator of clinical outcome.

Sasaki S, Nishihira K, Yamashita A, Fujii T, Onoue K, Saito Y PLoS One. 2022; 17(1):e0262413.

PMID: 35085285 PMC: 8794146. DOI: 10.1371/journal.pone.0262413.


Complement Inhibition Targeted to Injury Specific Neoepitopes Attenuates Atherogenesis in Mice.

Dai S, Liu F, Ren M, Qin Z, Rout N, Yang X Front Cardiovasc Med. 2021; 8:731315.

PMID: 34651027 PMC: 8505745. DOI: 10.3389/fcvm.2021.731315.